{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Arefanian H"],"pubmed_abstract":["<h4>Introduction</h4>Familial hypercholesterolemia, the highly prevalent form of dyslipidemia, is a well-known risk factor for premature heart disease and stroke worldwide. Statins, which inhibit 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase, are the first-choice treatment for dyslipidemias, and have been effective in reducing the risk of stroke and myocardial infarction. However, emerging evidence indicates that statins may increase the incidence of new-onset type 2 diabetes by reducing β-cell mass and function. Notably, past <i>in vitro</i> reports studying the effects of statins on β-cells were performed without including free fatty acids in the model. This factor should have been addressed since these agents are used to treat individuals with hyperlipidemia.<h4>Methods</h4>"],"journal":["Frontiers in endocrinology"],"pagination":["1383448"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11560436"],"repository":["biostudies-literature"],"pubmed_title":["Comparative efficacy, toxicity, and insulin-suppressive effects of simvastatin and pravastatin in fatty acid-challenged mouse insulinoma MIN6 β-cell model."],"pmcid":["PMC11560436"],"pubmed_authors":["Albeloushi S","Ahmad R","Qaddoumi M","Almansour N","Alzaid F","Bahman F","Al-Mulla F","Al Madhoun A","Williams MR","Arefanian H","Sindhu S","Al-Rashed F"],"additional_accession":[]},"is_claimable":false,"name":"Comparative efficacy, toxicity, and insulin-suppressive effects of simvastatin and pravastatin in fatty acid-challenged mouse insulinoma MIN6 β-cell model.","description":"<h4>Introduction</h4>Familial hypercholesterolemia, the highly prevalent form of dyslipidemia, is a well-known risk factor for premature heart disease and stroke worldwide. Statins, which inhibit 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase, are the first-choice treatment for dyslipidemias, and have been effective in reducing the risk of stroke and myocardial infarction. However, emerging evidence indicates that statins may increase the incidence of new-onset type 2 diabetes by reducing β-cell mass and function. Notably, past <i>in vitro</i> reports studying the effects of statins on β-cells were performed without including free fatty acids in the model. This factor should have been addressed since these agents are used to treat individuals with hyperlipidemia.<h4>Methods</h4>","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-07-16T20:19:02.764Z","creation":"2025-04-04T14:43:00.147Z"},"accession":"S-EPMC11560436","cross_references":{"pubmed":["39544235"],"doi":["10.3389/fendo.2024.1383448"]}}